Author: ZENTALIS PHARMACEUTICALS

Posted Date:

May 13, 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

ZENTALIS PHARMACEUTICALS

May 13, 2026
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

ZENTALIS PHARMACEUTICALS

May 12, 2026
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

ZENTALIS PHARMACEUTICALS

May 5, 2026
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ZENTALIS PHARMACEUTICALS

May 2, 2026
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

ZENTALIS PHARMACEUTICALS

April 21, 2026
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

ZENTALIS PHARMACEUTICALS

April 17, 2026
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

ZENTALIS PHARMACEUTICALS

April 9, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZENTALIS PHARMACEUTICALS

April 1, 2026
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

ZENTALIS PHARMACEUTICALS

March 17, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

ZENTALIS PHARMACEUTICALS

February 18, 2026